<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T01:18:35Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15326" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/15326</identifier><datestamp>2026-10-18T21:14:26Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The preventive role of levosimendan against bleomycin-induced pulmonary fibrosis in rats</dc:title><dc:creator>Gürbüzel, Mehmet</dc:creator><dc:creator>Sayar, Ilyas</dc:creator><dc:creator>Cankaya, Murat</dc:creator><dc:creator>Gürbüzel, Ahmet</dc:creator><dc:creator>Demirtas, Levent</dc:creator><dc:creator>Bakirci, Eftal Murat</dc:creator><dc:creator>Capoglu, Ilyas</dc:creator><dc:subject>Bleomycin</dc:subject><dc:subject>Erythrocyte enzymes</dc:subject><dc:subject>Levosimendan</dc:subject><dc:subject>Pulmonary fibrosis</dc:subject><dc:subject>Rat</dc:subject><dc:subject>Animals</dc:subject><dc:subject>Catalase</dc:subject><dc:subject>Erythrocytes</dc:subject><dc:subject>Glutathione Reductase</dc:subject><dc:subject>Hydrazones</dc:subject><dc:subject>Inflammation</dc:subject><dc:subject>Lung</dc:subject><dc:subject>Male</dc:subject><dc:subject>Phosphogluconate Dehydrogenase</dc:subject><dc:subject>Pyridazines</dc:subject><dc:subject>Rats</dc:subject><dc:subject>Rats, Sprague-Dawley</dc:subject><dc:subject>erythrocyte enzyme</dc:subject><dc:subject>sodium chloride</dc:subject><dc:subject>hydrazone derivative</dc:subject><dc:subject>pyridazine derivative</dc:subject><dc:subject>simendan</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>antiinflammatory activity</dc:subject><dc:subject>antioxidant activity</dc:subject><dc:subject>Article</dc:subject><dc:subject>bleomycin-induced pulmonary fibrosis</dc:subject><dc:subject>blood sampling</dc:subject><dc:description>Background In this study, the effects of levosimendan used in the treatment of acute congestive heart failure upon pulmonary fibrosis in rats induced with bleomycin (BL) were analyzed. Methods A total of 33 male Sprague-Dawley type rats were categorized into five groups randomly. About 2.5 U/kg BL was intratracheally administered to the rats in the BL, BL + L1, BL + L2, and BL + L3 groups, and 0.9% saline was intratracheally administered at the same rate to the control group. 0.3, 1, and 3 mg/kg levosimendan was intraperitoneally administered to the BL + L1, BL + L2, and BL + L3 groups, respectively. Blood and tissue samples were taken from the rats euthanized to determine the changes in erythrocyte enzyme activities and to conduct histopathological evaluations after 14 days. With values between 0 and 3, histopathological scoring damage was assessed by the presence of inflammation and fibrosis in a semiquantitative manner. Results Compared with those in the C group, glutathione reductase (GR) and Catalase (CAT) enzymes decreased in the BL group; compared with that in the BL group, GR increased in the BL + L1 and BL + L3 groups, 6-phosphogluconate dehydrogenase (6PGD) increased in the BL + L3 group, and CAT increased in the BL + L2 and BL + L3 groups (p &lt; 0.05). In the histopathological evaluation, fibrosis occurred in all rats in the BL group, and tissue damage was noticed to be generally less in the BL + L1, BL + L2, and BL + L3 groups (p &lt; 0.001). Conclusions The results obtained from biochemical and histopathological evaluations indicate that levosimendan had an anti-fibrotic effect without a dose-dependent response on pulmonary fibrosis. © 2015 Institute of Pharmacology, Polish Academy of Sciences.</dc:description><dc:publisher>Elsevier B.V.</dc:publisher><dc:date>2016</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/15326</dc:identifier><dc:identifier>https://doi.org/10.1016/j.pharep.2015.10.001</dc:identifier><dc:identifier>2299-5684</dc:identifier><dc:language>en</dc:language><dc:relation>Pharmacological Reports</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/15326</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>